Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2008-04-15
2008-04-15
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C435S243000, C435S252300
Reexamination Certificate
active
10837793
ABSTRACT:
A genetic deletion mutant liveE. colivaccine suitable for mass application to poultry, including chickens, is provided. Also provided is a safe and effective method to protect poultry against the ravages ofEscherichia colibacillosis infection and disease in which a live mutant aroA-gene deletedE. coliimmunogen is administered to chickens, turkeys and the like via mass application routes such as coarse sprays and drinking water.
REFERENCES:
patent: 4837018 (1989-06-01), Konishi et al.
patent: 5641491 (1997-06-01), Wilson et al.
patent: 6231871 (2001-05-01), Coloe
patent: 6350454 (2002-02-01), Thune
patent: 6902906 (2005-06-01), Chatfield
patent: 2004/0234550 (2004-11-01), Fan
patent: 0400958 (1990-12-01), None
patent: 0650733 (1995-05-01), None
Molina et al. (Infect.Immun. 58(8): 2523-2528. Aug. 1990).
Maskell et al (Microbial Pathogenesis. 293: 211-221. Mar. 1987. ABSTRACT only).
Stocker (J.Biotech. 83: 45-50. 2000).
Edwards et al. (J.Bacteriol. Sep. 1998. 170(9): 3991-3995).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, col. 247, pp. 1306-1310 (1990).
Gerald L. Cooper, et al, “Vaccination of chickens with aSalmonella enteritidisaroA live oralsalmonellavaccine” Microbial Pathogenesis 1990; 9: 255-265.
Erik P. Lillehoj, et al, “Vaccines against the avian enteropathogens Eimeria, Cryptosporidum andSalmonella” Animal Health Research Reviews 1(1); 47-65.
Nature, 1974, vol. 252, pp. 252-254.
George F. Dancey, et al., “Effect of Liposomal Model Membrane Composition on Immunogenicity,” The Journal of Immunology, Apr. 1978, vol. 120, No. 4, pp. 1109-1113.
R.M. La Ragione, et al., “The role of fimbriae and flagella in the colonization, invasion and persistence ofEscherichia coliO78:K80 in the day-old-chick model,” Epidemiology and Infection, 2000, vol. 124, pp. 351-363.
R.M. La Ragione, et al., “The role of fimbriae and flagella in the adherence of avian strains ofEscherichia coliO78:K80 to tissue culture cells and tracheal and gut explants,” Journal of Medical Microbiology, 2000, vol. 49, pp. 327-338.
S. N. Chatfield et al.; Vaccine; vol. 10; Issue 1; pp. 53-60; 1992.
Wang; Fowl. Sci. Tech. 14:24, 1998 (in Chinese, cited in Office Action from Chinese Patent Office. A copy of the Office Action is included in accordance with MPEP § 609.04(a)(III)).
Hassan et al.; Res. Microbiol. 141:839-850, 1990.
Wang et al.; Microb. Pathog. 27:55-59, 1999.
Peighambari et al.; Avian Dis. 46:287-297, 2002.
Fan Henry H.
Kumar Mahesh
La Ragione Roberto Marcello
Woodward Martin John
Graser Jennifer E.
Restreo-Hartwig Maria
Wyeth
LandOfFree
Avian E. coli vaccine for protection against colibacillosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avian E. coli vaccine for protection against colibacillosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avian E. coli vaccine for protection against colibacillosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3928011